Tarax (hydroxyzine) - Risk Of Qt Prolongation And Torsade De Pointes

ATARAX (hydroxyzine) Recall Summary Atarax (hydroxyzine), an antihistamine medication distributed across Canada, is being recalled due to a risk of QT prolongation and torsade de pointes—serious heart rhythm problems that can occur when taking this drug. This risk applies to all patients using Atarax. Health Canada has issued this recall to address the cardiac safety concern associated with the medication.

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2016-06-06

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/06b2df7a-8b31-426f-b719-1a8465c2fce7